New Horizons in IgA Nephropathy: Approach to Current and Emerging Therapies.

Cureus · 2026 · PMC13186295 · PMID 42164192

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interim analysis at nine months of the phase 3 trial (APPLAUSE-IgAN) replicated the effect and showed a trend toward improved eGFR preservation.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.